Major Players Swap Positions Among Industry Top 50
Key Developments Lead To Ups And Downs In The Middle Of Our Ranking
The second part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies sees a number of major firms sliding up and down the table.
You may also be interested in...
Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.
This article brings you a compilation of all the data from Generics Bulletin's recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.